Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- FDA Warns Yuki Gosei Kogyo against CGMP Violations
January 10, 2011
- Takeda Settles with 11 US Generic Firms Regarding Generics of Actos
January 10, 2011
- Memantine's Package Insert to Include No Precaution on Coadministration with Aricept
January 10, 2011
- Barclays Revises MTPC's Business Forecasts Upward
January 10, 2011
- RaQualia Ties Up with Eli Lilly for Pain Treatments
January 10, 2011
- Need to Reduce the Number of Generics Pointed Out at Chuikyo
January 10, 2011
- METI's Life Innovation-Related Budgets Down ¥230 Mil. to ¥8,280 Mil.
January 10, 2011
- Korosho to Support First-in-Human Trials in Earnest
January 10, 2011
- Research Spending down 7.9% to ¥1,193.7 Bil. for Pharma Industry in FY2009
January 10, 2011
- Prospects for Simultaneous Global Development: 1 (1)
January 3, 2011
- Eisai, Elan Settle Zonegran Off-Label Promotion Disputes
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (2)
January 3, 2011
- M3 to Expand Its e-Detailing Services in Oncology
January 3, 2011
- Seikagaku to File NDA for SI-6603 in Mid 2011
January 3, 2011
- PSJ to Raise Public Awareness of Drugs
January 3, 2011
- Ono Obtains Positive PIIb Results for Carfilzomib
January 3, 2011
- Otsuka HD Places Top Priority on Development of OPC-34712
January 3, 2011
- RG1678 Improves Negative Symptoms of Schizophrenia: Roche
January 3, 2011
- Sawai Asks Kyorin to Explain Why It Turned Down Merger Proposal
January 3, 2011
- Tasigna More Effective Than Glivec: Novartis
January 3, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…